Stroke in patients with heart failure and reduced left ventricular ejection fraction

Neurology

Volumn 54, Issue 2, 2000, Pages 288-294

  Pullicino, Patrick M ^a,d   Halperin, J L ^b   Thompson, J L P ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

Aspirin; Ejection fraction; Heart failure; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0034711763     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.54.2.288     Document Type: Review

References (40)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation, a major contributor to stroke in the elderly: the Framingham study. Arch Intern Med 1987;147:1561-1564.
2. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke: the Framingham study. JAMA 1983;250:2942-2946.
3. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20:301-306.
4. Falk RH. A plea for a trial of anticoagulation in dilated cardiomyopathy. Am J Cardiol 1990;65:914-915.
5. Ezekowitz M. Antithrombotics for left-ventricular impairment? Lancet 1998;351:1904.
6. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-1457.
7. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152.
8. The WARSS, APASS, PICSS, HAS, GENESIS Study Groups. The feasibility of a collaborative double-blind study using an anticoagulant. Cerebrovasc Dis 1997;7:100-112.
9. Chimowitz MI, Kokkinos J, Strong J, et al. The warfarin-aspirin symptomatic intracranial disease study. Neurology 1995;45:1488-1493.
10. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-833.
11. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1999;150: 769-773.
12. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074-1080.
13. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993;72:310-313.
14. Loh E, Sutton MSJ, Wun CCC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
15. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-531.
16. Segal JP, Stapleton JF, McClellan JR, Waller BF, Harvey WP. Idiopathic cardiomyopathy: clinical features, prognosis and therapy. Curr Probl Cardiol 1978;3:1-49.
17. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626-634.
18. Pullicino P, Xuereb M, Aquilina J, Piedmonte MR. Risk factors for stroke following acute myocardial infarction. Cerebrovasc Dis 1991;1:210-215.
19. Pullicino P, Mifsud V, Kaliszky Z, Graham S. Cerebral infarction in patients with low cardiac ejection fraction. J Neuroimaging 1998;8:122.
20. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JGF. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607-612.
21. Bogousslavsky J, Regli F. Unilateral watershed cerebral infarcts. Neurology 1986;36:373-377.
22. Bladin CF, Chambers BR. Clinical features, pathogenesis, and computed tomographic characteristics of internal watershed infarction. Stroke 1993;24:1925-1932.
23. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
24. Katz SD, Marantz PR, Biasucci L, et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993;126:141-146.
25. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;31:749-753.
26. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1998;334:1349-1355.
27. Garg R, Yusuf S, the Collaborative Group on ACE Inhibitor Trials. Overview of randomized controlled trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273: 1450-1456.
28. CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II: a randomised trial. Lancet 1999;353:9-13.
29. Goldstein S, Hjalmarson A. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 1998;(suppl 1):364.
30. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
31. Kyrle PA, Korninger C, Gossinger H, et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 1985; 54:521-523.
32. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med 1997;157:1237-1240.
33. The Sixty-Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2: 989-993.
34. Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. An assessment of long-term anticoagulant administration after cardiac infarction. Br Med J 1964;837:843.
35. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
36. EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-1262.
37. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87(suppl 6):VI94-VI101.
38. Falk RH, Pollak A, Tandon PK, Packer M, PROMISE Investigators. The effect of warfarin on prevalence of stoke in patients with severe heart failure. J Am Coll Cardiol 1993;21: 218A. Abstract.
39. Cioffi G, Pozzoli M, Forni G, et al. Systemic thromboembolism in chronic heart failure. Eur Heart J 1996;17:1381-1389.
40. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.